OPHTHALMOLOGY
Our Approach
Established in 1999, the Ophthalmology division of Micro Labs operates with the goal of producing and selling high-quality eye care products at an affordable price in India and worldwide. At the very outset, we have made a significant impact with the introduction of Microflox DX®, a steroid with an anti-infective combination that revolutionized post-operative care. This was the first time a steroid with Fluoroquinolone was introduced in the Ophthalmic market.
The company's R&D team developed Flurisone, the first Indian formulation of Fluorometholone, which opened doors for the development of molecules and formulations available in the global market to be produced in India. We have since introduced a wide range of ophthalmic products, including Lubrex®, the first Indian formulation of Carboxymethylcellulose for the management of Dry Eyes, Misopt®, the first Indian combination of Dorzolamide plus Timolol for the management of Glaucoma, and Levobact®, the first formulation of Levofloxacin eye drop for the treatment of ocular infections in pediatric patients. Recently, we have introduced preservative-free eye ointments for the first time in India in world-class packaging and the first self-preserved anti-glaucoma medication, Travo-Z® (Travoprost). We are also the first in the world to launch the Triple FDC eye drops- Trisopt®.
Our success in the ophthalmic industry caught the attention of global players, leading to a strategic partnership with LG Life Sciences, South Korea, in 2005. The partnership allowed LG to market their Visco-elastic, LG-Hyal 2000 Injections in India by leveraging our marketing team.
In 2006, Micro Labs established a state-of-the-art ophthalmic manufacturing facility at Bangalore that meets the highest quality and regulatory standards of both American and British medical review authorities—USFDA & MHRA (UK)—propelling our expansion to global markets.
For more information, visit our website dedicated for ophthalmology : https://visionmicro.in/
